Clinical Trials
10 trialsNCT05104983 2026-01-22
TSC-STEPS
Children's Hospital Medical Center, Cincinnati
Phase 2 Recruiting
NCT05626634 2025-12-03
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals
Phase 2 Completed
NCT03944447 2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2 Unknown
NCT04737174 2022-04-06
ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors
ES Therapeutics Australia Pty Ltd
Phase 2 Withdrawn
NCT02451696 2021-09-01
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
NYU Langone Health
Phase 2 Completed
NCT03650452 2021-02-18
ELEKTRA
Takeda
Phase 2 Completed
NCT03356769 2020-06-09
Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
Peking Union Medical College Hospital
Phase 2 Unknown
NCT00179517 2019-07-17
Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT01997255 2016-05-05
Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
Baylor College of Medicine
Phase 2 Withdrawn
NCT01545518 2014-09-01
IVIG Treatment for Refractory Immune-Related Adult Epilepsy
Emory University
Phase 2 Terminated